Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07307768 · ClinicalTrials.gov registry record · Phase 1
Ketamine Biomarker Validation
A Phase 1 study, sponsored by Soterix Medical.
- Not yet
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07307768 is a Phase 1 study that has not yet begun recruiting, run by Soterix Medical. The registered enrollment target is 20 participants.
The verdict
NCT07307768, a Phase 1 study, has not yet begun recruiting, sponsored by Soterix Medical.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
We will be developing an EEG-based biomarker for the effects of ketamine infusion in patients with Depression. We will be analyzing the effects of ketamine infusion on Depression symptoms and EEG signals.
Interventions
- DRUG Ketamine (0.5 mg/kg)
- DRUG Ketamine (0.25 mg/kg)
- DRUG Ketamine (0.75 mg/kg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-12-20 |
| Est. Completion | 2028-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07307768
The ClinicalTrials.gov registry entry for NCT07307768 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Soterix Medical, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ketamine (0.5 mg/kg) is the first listed.
NCT07307768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07307768 about?
NCT07307768 is a clinical study titled "Ketamine Biomarker Validation". We will be developing an EEG-based biomarker for the effects of ketamine infusion in patients with Depression. We will be analyzing the effects of ketamine infusion on Depression symptoms and EEG signals.
What is the current status of trial NCT07307768?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-12-20. Estimated completion is 2028-03-01.
What interventions are being tested in trial NCT07307768?
The interventions under investigation include: Ketamine (0.5 mg/kg) (DRUG), Ketamine (0.25 mg/kg) (DRUG), Ketamine (0.75 mg/kg) (DRUG).
Who is sponsoring clinical trial NCT07307768?
This trial is sponsored by Soterix Medical, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.